Skip to main content

RINVOQ™

Upadacitinib (ABT-494) is a JAK1 selective inhibitor being investigated to treat rheumatoid arthritis, Crohn's disease, ulcerative colitis, atopic dermatitis, psoriatic arthritis, axial SpA Giant Cell Arteritis and Takayasu Arteritis.

Type of Molecule

Small Molecule

Target

JAK1

Product Type

New Indication
Potential Indication Region Phase (1, 2, 3, Submitted)
Ankylosing Spondylitis US - Submitted,EU - Approved
Approved
Atopic Dermatitis US - Submitted,EU - Approved
Approved
Axial SpA n/a
Phase 3
Crohn's Disease n/a
Phase 3
Giant Cell Arteritis n/a
Phase 3
Psoriatic Arthritis US - Submitted,EU - Approved
Approved
Rheumatoid Arthritis US,EU
Approved
Takayasu Arteritis n/a
Phase 3
Ulcerative Colitis n/a
Phase 3